UK Regulator Revokes Chikungunya Vaccine Authorization Over Safety Issues

The UK's MHRA has withdrawn marketing authorization for the IXCHIQ chikungunya vaccine. This action follows advice from the Commission on Human Medicines and reports of serious adverse reactions, including hospitalizations and deaths, with some cases showing chikungunya-like symptoms and rare neurological events. Healthcare professionals are now advised to cease prescribing and administering the vaccine, and to dispose of existing stock, impacting public health and vaccine availability.